Clinuvel Pharmaceuticals Ltd. announced the appointment of Mr. Willem Blijdorp as a Non-Executive Director of the Company. Mr. Blijdorp's appointment comes as Clinuvel prepares the commercial distribution of SCENESSE for the rare disease erythropoietic protoporphyria (EPP) throughout the European Union. Mr. Blijdorp is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products.

He managed B&S International for 27 years as CEO and remains actively involved in the company's expansion strategy, helping it to become one of the trading houses globally with a compounded annual growth rate of 10% for the past decade.